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Epigenetic alterations represent a sort of functional modifications related to the genome
that are not responsible for changes in the nucleotide sequence. DNA methylation is one
of such epigenetic modifications that have been studied intensively for the past several
decades. The transfer of a methyl group to the 5 position of a cytosine is the key feature
of DNA methylation. A simple change as such can be caused by a variety of factors,
which can be the cause of many serious diseases including several neurodegenerative
diseases. In this review, we have reviewed and summarized recent progress regarding
DNA methylation in four major neurodegenerative diseases: Alzheimer’s disease (AD),
Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis
(ALS). The studies of these four major neurodegenerative diseases conclude the strong
suggestion of the important role DNA methylation plays in these diseases. However,
each of these diseases has not yet been understood completely as details in some areas
remain unclear, and will be investigated in future studies. We hope this review can provide
new insights into the understanding of neurodegenerative diseases from the epigenetic
perspective.
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INTRODUCTION
Epigenetic refers to the study of mitotically or meiotically her-
itable changes in gene functions that cannot be explained by
changes in DNA sequence. In most cases, it acts as the her-
itable regulation of DNA transcription by DNA methylation,
histone modification and expression of noncoding RNAs. Since
R. D. Hotchkiss (Hotchkiss, 1948) discovered that DNA can be
methylated at the 5-position of cytosine in 1948, the mysteri-
ous veil on epigenetics has been gradually lifted. A study of in
discordant twins pointed out that epigenetics can make a differ-
ence, even in a pair of monozygotic twins (Fraga et al., 2005).
Fraga et al. uncovered that even if sharing a common geno-
type, twins still showed different penetrance of various diseases
such as neurological disorders. Among epigenetic mechanisms,
DNA methylation is a crucial epigenetic marker that has been
most widely studied. Alterations of DNAmethylation are involved
in many human diseases including cancer and neurological
disorders.
Neurodegenerative diseases are one kind of neurological dis-
eases featuring the progressive loss and even final death of
neurons. The specific causes and pathological mechanisms of
neurodegenerative diseases have not been completely understood.
Recently, a large amount of evidence have emerged to show a
shared non-Mendelian property between DNA methylation and
neurodegenerative diseases, a connection that has peaked research
interest for over two decades.
The main purpose of this review is to provide an overview on
the involvement of DNA methylation in the pathology of neu-
rodegenerative disease. We will begin by outlining the concept
of DNA methylation, then focus intensively on recent progress
made in the study of DNA methylation in four major neurode-
generative diseases: Alzheimer’s disease (AD), Parkinson’s disease
(PD), Huntington’s disease (HD), and amyotrophic lateral sclero-
sis (ALS). We will discuss in depth the relationship between DNA
methylation and neurodegenerative diseases, as well as the causal
and consequential effect of DNA methylation in these diseases.
THE PRINCIPLE OF DNA METHYLATION
As the most widely characterized epigenetic modification, DNA
methylation in eukaryotes is found nearly exclusively at cytosine
residues. A methyl group is added at the 5-position of cyto-
sine before a guanine and gene silencing is frequently associated
with this modification. This dinucleotide unit is always written
as CpG, representing a combination of a cytosine, the follow-
ing guanine and a phosphate group between them. Regions with
high concentration of CpGs are called CpG islands, which usu-
ally locate in promoter region of genes, a place where most CpGs
in the human genome exist. Cytosines are usually not methy-
lated in CpG islands, but for some particular functions, such as
X chromosome inactivation, methylation of CpG islands is also
required. On the other hand, predominantly located in repetitive
or centromeric sequences, CpGs outside CpG islands are usu-
ally methylated (Reik et al., 2001; Bird, 2002). Data showed that
unmethylated regions of the genome are protected from DNA
methylation by a combination of factors involving very high CpG
densities and histone modifications, while the remaining bulk of
the genome is methylated as the default state (Edwards et al.,
2010). CpG methylation within promoter and intragenic sites
have been extensively studied and recent interest have also arisen
regarding non-CpG methylation, which refers to the methylation
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that occurs at cytosines of non-CpG dinucleotides, such as CA,
CT, or CC. While CpG methylation can occur whenever gene
silencing is needed during the life span of a cell, non-CpGmethy-
lation is dominantly present in embryonic stem cells (Haines
et al., 2001; Dodge et al., 2002; Lister et al., 2009) as well as in
neural development (Lister et al., 2013).
More specifically, 5-methylcytosine (5mC) is produced by
transferring a methyl group from an S-adenosyl-L-methionine
(SAM) to the cytosine with the help of DNA methyltrans-
ferases (DNMTs) (Figure 1). Five kinds of proteins—DNMT1,
DNMT2, DNMT3a, DNMT3b, and DNMT3L are major mem-
bers of DNMT family (Bestor, 2000). The functions of DNMT
in DNA methylation can be divided into maintenance methy-
lation and de novo methylation. DNMT1 is involved in main-
tenance methylation, which refers to the process of copying
DNA methylation profiles to the daughter strands during DNA
replication. DNMT3a and DNMT3b are de novo methyltrans-
ferases that establish DNA methylation patterns in early devel-
opment. DNMT3L has no catalytic activity but can assist the de
novo methyltransferases by improving their ability of binding to
DNA and stimulating their activity. Instead of methylating DNA,
DNMT2 was shown to methylate the anticodon loop of aspartic
acide transfer RNA at cytosine-38 (Goll et al., 2006). Recognizing
and binding of methyltransferases to 5-methylcytosines requires
methyl-CpG binding domain (MBD) proteins, which are MeCP2,
MBD1, MBD2, MBD3, and MBD4 in mammals (Fatemi and
Wade, 2006). In addition to 5mC, there exists another kind of
methylated cytosine, 5-hydroxymethylcytosine (5hmC), which is
consequence of the oxidation of 5mC that is catalyzed by the ten-
eleven translocation (TET) proteins. In turn, 5hmC also can be
deaminated to 5mC via the mediation of AID/APOBEC family
proteins. 5hmC in mammalian DNA was first described in the
early 1970s (Penn et al., 1972), however, it has been poorly stud-
ied until recently when studies found that 5hmC is present in
mouse neurons as well as in embryonic stem cells (Kriaucionis
and Heintz, 2009; Tahiliani et al., 2009). Since then, it has been
substantiated that 5hmC can influence the regulation of gene
expression, and the conversion of 5mC to 5hmC may contribute
to DNA demethylation that, in most cases, associates with gene
activation (Bhutani et al., 2011; Guo et al., 2011a).
DNA methylation works in harmony with histone acetylation
to control memory formation and synaptic plasticity (Miller et al.,
2008), and it also has a possible impact on genetic and neuronal
function affecting behaviors (Day and Sweatt, 2010). Besides,
the connection among DNA methylation, chromatin structure
and gene silencing has been extensively studied for many years,
and the gene silencing is thought to be an epigenetic interven-
tion on neurodegenerative diseases like AD (Scarpa et al., 2006).
Therefore, we can believe that there is a very strong potential link
between DNA methylation and neurodegenerative diseases as we
will talk about below.
DNA METHYLATION AND ALZHEIMER’s DISEASE
INTRODUCTION TO ALZHEIMER’S DISEASE
AD is the most common form of dementia, which brings acute
suffering to its patients. Eleven percent of people age 65 or older
and 32% of people age 85 or older are afflicted by this disease. The
general symptom pattern begins with the gradually worsening of
ability to remember new information. The patient’s cognitive and
functional abilities decline as the disease progresses. Extracellular
neuritic plaques, intracellular neurofibrillary tangles and neu-
ronal loss are the main pathological hallmarks in AD brains. AD
is ultimately fatal and has become the sixth leading cause of death
in the United States (Thies et al., 2013).
The cause of AD is still unclear. Numerous genetic and envi-
ronmental risk factors are involved in the etiology and pathogen-
esis of AD, including alterations in the expression of thousands
of genes, amyloid β-peptide (Aβ) deposition, tau hyperphospho-
rylation, inflammation, oxidative stress, energy metabolism, and
aberrant re-entry into the cell cycle/apoptosis. It’s worth noting
that when Aβ-inducingmutations are absent, thesemolecular and
genetic factors do not have absolute penetrance in causing the
disorder (Mastroeni et al., 2011).
Two dominant hypotheses to explain the disease are Aβ
hypothesis and tau hypothesis. Redundant Aβ is considered a
main contributor to the dysfunction and degeneration of neu-
rons that occurs in AD. Aβ, a 38–43 amino acid peptide, is gained
from sequential β- and γ-secretase cleavages of amyloid-β pre-
cursor protein (APP). When the cleavage site lies within the Aβ
sequence, another APP processing enzyme, α-secretase, precludes
Aβ formation. Beta-site APP cleaving enzyme 1 (BACE1) is the
major β-secretase in the brain. γ-Secretase consists a minimum 4
proteins: presenilin 1 (PS1) or presenilin 2 (PS2), nicastrin (Nct),
presenilin enhancer 2 (Pen2), and anterior pharynx defective 1
(Aph-1) (Chow et al., 2010). Another hypothesis, the tau hypoth-
esis, is based on the hyperphosphorylation of tau in patients
with AD. How phosphorylation influences tau function is only
poorly understood, but it negatively regulates the binding of tau
to microtubules. Hence, functions of tau such as microtubule
stabilization and the regulation of axonal transport may be com-
promised, possibly contributing to disease. Moreover, interactive
enhancements between Aβ and tau were also proposed recently
(Ittner and Gotz, 2011).
AD can be generally categorized into two divisions. Less than
2% of AD cases are early-onset Alzheimer’s disease (EOAD),
which onsets prior to age 60 with genetic mutations in APP, prese-
nilin 1, or presenilin 2 genes. Mutations in these genes dysregulate
the APP pathway and directly lead to Aβ plaque accumulation,
a major pathological hallmark of AD. Other cases which are
sporadic and manifest symptoms after age 60, are termed late-
onset Alzheimer’s disease (LOAD). At least one apolipoprotein
4 allele (APOE-4) is found in approximately 50–65% of LOAD
cases, while the global population prevalence of the allele is only
approximately 20–25% (van der Flier et al, 2011).
DNA METHYLATION MODIFICATION EVIDENCE IN AD
DNA methylation modifications related to AD can be divided
into two groups: global DNA methylation modifications and
gene-specific DNA methylation modifications. Global DNA
hypomethylation and specific gene hypermethylation are the
overall phenomenon among studied AD cases.
Global methylation modification and AD
Most studies support the view that on the whole-genome
scale, the DNA methylation level in AD cases is lower than in
comparison with normal individuals. Direct evidence came from
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FIGURE 1 | Metabolic pathway of DNAmethylation. HCY/SAM cycle
ensures the continuous transport of methyl group from SAM to cytosine,
providing the rawmaterial of DNAmethylation. Enzymes are shown in redwhile
substrates and products are shown in black. Red line marks the step where the
pathway can be blocked by deficiency of folate, vitamin B6 and vitamin B12, and
such block results in HCY accumulation and other biological effects.
studies in monozygotic twins. A postmortem study of rare sets
of monozygotic twins discordant for AD reported significantly
reduced levels of DNA methylation in temporal neocortex neu-
ronal nuclei of the AD twin, which provided the potential for AD
discordancy in spite of genetic similarities. With specific mark-
ers, decrement in DNAmethylation was observed in AD reflected
among neurons, reactive astrocytes, and microglia (Mastroeni
et al., 2009). Research also recognized a dramatic decrease in
AD patients of far-going epigenetic markers and regulators in
neurons from control entorhinal cortex layer II, consistent with
the high vulnerability of this brain region to AD pathology. The
result indicates that global DNA and RNA methylation status are
significantly diminished in AD in this region (Mastroeni et al.,
2010). This trend of global hypomethylation was further con-
firmed in a more recent and direct study, in which decrements
of 5mC and 5hmC were shown in AD patients’ hippocampus by
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a quantitative immunohistochemical method (Chouliaras et al.,
2013). A similar result was also shown in a cell line. Using the AD
model cell line H4-sw, which harbors the Swedish mutation and
produces high levels of the toxic form Aβ, global methylation sta-
tus were analyzed. Among the total 6296 differentially methylated
CpG sites, 23% were shown to be hypermethylated while others
were hypomethylated (Sung et al., 2011).
However, such a conclusion is not supported by all the
evidence. For instance, a postmortem human frontal cortex
genome-wide DNA methylation study also showed general and
mild discordant DNAmethylation in LOAD-diseased tissue inde-
pendent of the age factor, while both hypomethylation and
hypermethylation were found (Bakulski et al., 2012). Moreover,
another postmortem human frontal cortex study showed a trend
of global DNA hypermethylation in AD cases (Rao et al., 2012).
It is noteworthy that DNA hypomethylation tendency in AD is
mainly supported by immunoassays, but the opposite tendency
has been observed through bisulfite treatment, which is a direct
interrogation of DNA.
Gene specific DNA methylation modification and AD
Researchers have also traced the methylation modification of a
number of specific genes, which are believed to be related to AD.
Such studies usually concentrate on the gene promoter region, in
whichDNAmethylation regulates the expression of genes.Wewill
divide these genes into six sections and introduce findings in each
section.
Aβ-generation-related genes. APP, PS1, and BACE1 play crucial
roles in the generation of Aβ. Therefore, the promoter regions of
their genes have been studied in many different researches.
Recent results overall suggest that there is no correlation
between APP methylation modification and AD. A large-scale
postmortem study involving frontal cortex and hippocampus
found no difference in APP gene promoter region methylation
among all stages of AD patients and healthy controls. The preser-
vation of DNA methylation status in postmortem brain samples
was also confirmed (Barrachina and Ferrer, 2009). Another post-
mortem study focusing on the cortex and cerebel observed no
methylated CpG in APP promoter regions in any familial AD
patients and their healthy comparisons (Brohede et al., 2010).
However, a study in SH-SY5Y cell lines indicated that the pro-
moter of APP is capable to be hypomethylated (Guo et al.,
2011b).
The situation of PSEN1 (the gene encoding PS1) seems more
apparent, since almost every study in this field reports PSEN1
promoter hypomethylation and the resulting overexpression of
PSEN1 as factors leading to AD. Firstly, studies in neuroblas-
toma cell lines (Fuso et al., 2005) and mouse (Fuso et al., 2008,
2011b) showed that PSEN1 can be overexpressed through DNA
hypomethylation. Further investigations in mouse ruled out the
possibility that hypomethylation of PSEN1 promoter is the con-
sequence of amyloid production (Fuso et al., 2012a). Finally, sim-
ilar hypomethylation was observed in postmortem study (Wang
et al., 2008). However, it should be noted that almost all papers
reporting PSEN1 hypomethylation in AD came from the same
laboratory, and these results need to be validated by independent
laboratories.
It has also been reported that BACE1 expression can be
upregulated via demethylation of at least two CpG sites at posi-
tion +298 and +351 in the 5′-untranslated region in BV-2
microglial cells (Byun et al., 2012).
Aβ-degradation-related genes. Aβ peptides are proteolytically
degraded within the brain mainly by neprilysin (NEP) (Iwata
et al., 2000) and insulin-degrading enzyme (IDE, insulysin)
(Kurochkin and Goto, 1994). The endolytic degradation of Aβ
peptides within microglia by NEP and related enzymes is sig-
nificantly enhanced by apolipoprotein E (ApoE). Similarly, Aβ
extracellular degradation by IDE is facilitated by ApoE (Jiang
et al., 2008). There are three major isoforms of ApoE: ApoE2,
ApoE3, and ApoE4. Among them, ApoE3 is the most common
isoform in the population, while ApoE4 has been shown to confer
dramatically increased risk for LOAD (Roses et al., 1995).
It has been reported that Aβ causes NEP promoter region
hypermethylation, which consequently suppresses NEP’s expres-
sion in mRNA and protein levels, reduces the Aβ clearance and
probably elevates Aβ accumulation. This could be part of a vicious
cycle which plays a role in the pathophysiology of AD (Chen et al.,
2009). Sortilin-related receptor (SORL1, also known as SORLA,
SORLA1, or LR11) is a neuronal ApoE receptor. Its connection
with AD is based on its reduction in AD brains and its ability to
lower Aβ levels (Offe et al., 2006). The SORL1 gene showed dif-
ferences in its expression among peripheral blood leukocytes, and
it may act as a marker of aging in this tissue. It has been shown
that SORL1 promoter DNA methylation could serve as one of the
mechanisms in charge of the differences in expression observed
between blood and brain for both healthy elders and AD patients
groups (Furuya et al., 2012a).
Tau-related genes. Activity and expression level of glycogen syn-
thase kinase 3β (GSK3β), the major kinase that phosphorylates
tau in the brain, are increased in AD brains (Nicolia et al., 2010).
A study in human neuroblastoma SK-N-BE cell line and
TgCRND8 mouse showed that GSK3β gene’s promoters can be
hypomethylated by inhibiting methylation activity through B
vitamin deficiency and such hypomethylation results in the over-
expression of GSK3β (Nicolia et al., 2010). It was also reported
that inhibition of GSK3β reduces the expression of DNMT3A
and causes hypomethylation of related genes in mouse embryonic
stem cells (Popkie et al., 2010).
Genes involved in metabolic pathways. Another finding is that
rare haplotypes may be associated with the risk of AD through a
possible modulation of the methylation of the ornithine transcar-
bamylase (OTC) promoter. In spite of being mostly speculative,
it might suggest a deregulation of urea cycle in AD (Bensemain
et al., 2009).
Ribosomal DNA (rDNA). Ribosomal deficits are verified in mild
cognitive impairment (MCI), which often represents an early
stage AD as well as the potential of advanced AD (Ding et al.,
2005). Although an early study didn’t detect any differential
methylation pattern of rDNA genes in total peripheral blood
cells in elderly and AD subjects (Speranca et al., 2008), it was
reported later that the rDNA promoter become hypermethylated
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in studied AD cerebrocortical samples, suggesting that rDNA
hypermethylation could be implicated in AD (Pietrzak et al.,
2011).
Other genes. The complexity of AD and epigenetics leads to
an endless stream of research. One study suggested that behav-
ioral and psychological symptoms in dementia patients may be
caused by the methylation disturbance of circadian gene (Liu
et al., 2008). In addition, DNA methylation status of repetitive
elements long interspersed element-1 (LINE-1) was shown to
be increased in AD patients compared with healthy volunteers
(Bollati et al., 2011). Moreover, various potential functions of
neuroglobin (NGB) have been exhibited and found to be able
to reduce the severity of stroke and AD (Khan et al., 2007).
A 5-aza-2′-deoxycytidine (a methyltransferase inhibitor) treat-
ment analysis indicated that DNA methylation/demethylation
may be involved in regulating NGB tissue-specific expression
(Zhang et al., 2011). Another separate research implies that long
telomeres with hypomethylation tend to shorten faster, while cells
bearing short telomeres with hypomethylation tend to enter into
a senescent state under elevated OS stress in AD more easily.
It has been validated that this trend can be reversed by vita-
min E (Guan et al., 2012). Rao et al. reported hypomethylated
cyclooxygenase-2 (COX-2) (one of the arachidonic acid (AA) cas-
cade markers) and brain-derived neurotrophic factor (BDNF)
promoter regions in AD brain, while the promoter region of
cAMP response element-binding protein (CREB), which regu-
lates the transcription of BDNF, was shown to be hyperme-
thylated. Their study also found a significant increase in DNA
methylation at the promoter region of synaptophysin (SYP) and
decreased methylation of the NF-kB promoter CpG region in the
AD (Rao et al., 2012). S100A2 is a member of the S100 family
of calcium binding proteins while SORBS3 encodes a cell adhe-
sion molecule expressed in neurons and glia. The decrement
of S100A2 and increment in SORBS3 CpG methylation in AD
brains were reported from a postmortem study (Siegmund et al.,
2007).
Some other genes involved in AD were also investigated, but
no DNA methylation differences have been found in these genes.
These genes include synaptosomal-associated protein 25 (SNAP-
25) (Furuya et al., 2012b), SIRT3, SMARCA5, CDH1 (Silva et al.,
2008), 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNP), and
dihydropyrimidinase-like 2 (DPYSL2) (Silva et al., 2013).
DNA METHYLATION AND PARKINSON’S DISEASE
INTRODUCTION TO PARKINSON’S DISEASE
PD is the second most common neurodegenerative disorder after
AD. According to the PD Foundation, about 1 million people
in the United States and more than 4 million people worldwide
are affected with this disease. The prevalence of PD in industrial-
ized countries is generally estimated at about 1–2% of population
over 60 years of age, and increases to 3–5% in people above 85
years old. This neurodegenerative disorder is characterized by the
progressive loss of substantia nigra dopaminergic neurons and
striatal projections, causing the typical symptomatology: muscle
rigidity, bradykinesia, tremor, and postural instability (de Lau and
Breteler, 2006).
Although more than 90% of the cases can be interpreted as
sporadic PD, the greatest insights into PD etiology have come
from the study of familial forms. In recent years, mutations in
six genes have been identified as causes of PD: SNCA (which
encodes α-synuclein), PARK2 (parkin), PINK1 (PTEN-induced
kinase protein 1),UCHL1 (ubiquitin carboxyl-terminal hydrolase
isozyme L1), DJ1 (protein DJ-1), and LRRK2 (leucine-rich repeat
serine/threonine-protein kinase 2). The hallmark neuropatholog-
ical sign of PD is the presence of fibrillar aggregates of misfolded
α-synuclein called Lewy bodies, which accumulate in the same
sites where neuronal loss is found (Urdinguio et al., 2009).
Although PD is less studied than AD in terms of the relation
to epigenetics, this section aimed to review the interrelation of
PD and DNA methylation is organized into two parts. First part
is exploring what genetic factors of PD pathogenesis might be
affected by DNAmethylation, and the other one is aimed to show-
ing how environmental factors could get involved in the alteration
of DNA methylation leading to PD.
GENETIC FACTORS, DNA METHYLATION AND PD
DNA methylation regulation of α-synuclein
Considering that α-synuclein makes a major contribution to the
formation of Lewy bodies and even to the entire pathogenesis of
PD, we start from discussion on impact DNA methylation has on
α-synuclein.
An earlier study revealed that the DNA methylation pattern
within the α-synuclein (SNCA) gene promoter region was altered
in the blood samples of patients with alcoholism, which was
significantly associated with their increased homocysteine lev-
els (Bonsch et al., 2005). This is the first study, to the best
of our knowledge, to show a correlation between DNA methy-
lation and α-synuclein in certain syndromes. Later on, it has
been reported that the methylation of human SNCA intron 1
decreased gene expression while inhibition of DNA methyla-
tion activated its expression in the brains of PD patient (Jowaed
et al., 2010), which further strengthens the link. Although analysis
of postmortem brain did not reveal regional specific methyla-
tion differences in the putamen and anterior cingulate between
PD and healthy individuals, methylation was found specifi-
cally and significantly reduced in the substantia nigra of PD
patients (Matsumoto et al., 2010). In addition, single CpG analy-
sis reflected fluctuating methylation levels at different locations
in various brain regions and LBD stages, even if the overall
methylation levels in the promoter and intron 1 of α-synuclein
gene were reported to be similarly low both in Lewy body dis-
ease (LBD) patients and controls(de Boni et al., 2011). These
results suggest a potential role of DNAmethylation in α-synuclein
neuropathogenesis.
Unfortunately, in the blood cell sample of a PD patient with
heterozygous SNCA A53T mutation, α-synuclein expression was
found to be monoallelic because of epigenetic silencing of the
mutated allele through histone modification instead of DNA
methylation (Voutsinas et al., 2010). Rather than altering DNA
methylation, α-synuclein negatively regulated PKC-delta expres-
sion in human dopaminergic neurons by reducing histone mod-
ification (Jin et al., 2011). Moreover, no differential methylation
of SNCA was observed in white blood cell DNA of PD patients
Frontiers in Aging Neuroscience www.frontiersin.org December 2013 | Volume 5 | Article 85 | 5
Lu et al. DNA methylation and neurodegenerative diseases
compared to the neurologically normal controls (Richter et al.,
2012).
Nonetheless, the interaction of DNMT and α-synuclein has
also been tested. Reduction of nuclear DNMT1 levels was
observed in postmortem brain samples from PD patients and in
the brains of α-synuclein transgenic mice, underlying a mecha-
nism in which DNMT1 might be excluded from the nucleus by
α-synuclein, and the segregation of DNMT1 further resulted in
hypomethylated CpG islands upstream of α-synuclein(Desplats
et al., 2011).
Overall, these results indicate that there is a good chance that
DNA methylation is involved in the regulation of α-synuclein
gene expression, even if its specific role still remains to be further
clarified.
DNA methylation in other genes related to PD
In addition to α-synuclein, several other genes also have been
examined to find whether they are associated with PD in a
DNA-methylation-regulated way.
Tumor necrosis factor α (TNF-α) is a critical inflammatory
cytokine and increased TNF-α is associated with dopaminergic
cell death in PD. It has been suggested that a lesser extent of
methylation of the TNF-α promoter in human substantia nigra
cells could uphold the increased vulnerability of dopaminergic
neurons to TNF-α regulated inflammatory reactions (Pieper et al.,
2008). Because TNF-α overexpression induces apoptosis in neu-
ronal cells and TNF-α levels were rather high in the cerebrospinal
fluid of PD patients (Mogi et al., 1996), we can speculate that
DNA methylation might be the reason for such overexpression
of TNF-α. As is well known, the parkin gene plays a relatively
important part in the emergence and development of PD. The
methylation levels of the parkin gene promoters were analyzed in
samples from PD patients heterozygous for parkinmutations, PD
patients without parkinmutations, and normal controls, however,
no significant difference was observed among the three groups,
indicating that parkin promoter methylation alone is unlikely to
impact the pathogenesis and development of PD (Cai et al., 2011).
Ubiquitin c-terminal hydrolase L1 is a member of one subfamily
of deubiquinating enzymes that remove ubiquitin from ubiquiti-
nated substrates in the ubiquitin proteasome degradation system.
Dysfunction of UCHL-1 has been implicated in the pathogen-
esis of neurodegenerative disorders, including PD. The UCHL1
promoter was found hypermethylated in diverse types of cancer
(Kagara et al., 2008; Yu et al., 2008), however, analysis of UCHL1
promoter in the hippocampus and frontal cortex of PD patients
and controls displayed no significant differences in CpG methy-
lation between these two groups (Barrachina and Ferrer, 2009).
A large-scale sequencing analysis of postmortem brain samples
identifiedmethylation and expression changes associated with PD
risk variants in PARK16/1q32, GPNMB/7p15, and STX1B/16p11
loci, suggesting that some other PD-related genes could also be
epigenetically modified in PD brains (Plagnol et al., 2011).
More recently, it was reported that the expression of clock
genes was altered in both PD patients and in animal models of the
disease (Cai et al., 2010; Hood et al., 2010). Promoter methylation
analysis of seven clock genes in blood samples of PD revealed that
most clock gene promoters were short of methylation, suggesting
that altered promoter methylation may contribute to the aberrant
expression of clock genes in PD (Lin et al., 2012). A genome-wide
methylation analysis of PD with quantities DNA methylation
levels found reduced methylation of the cytochrome P450 2E1
gene in PD patients’ brains compared to the controls, which
suggests that epigenetic variants inde-toxifying enzymes, such
as cytochrome genes, may add to PD susceptibility (Kaut et al.,
2012).Mesodiencephalic dopaminergic (mdDA) neurons, located
in the ventral mesodiencephalon, are involved in severely affected
neurodegenerative diseases such as PD. Emerging evidence shows
that epigenetic mechanisms including DNA methylation play an
important role in mdDA development, maturation and mainte-
nance (van Heesbeen et al., 2013). Furthermore, other specific
genomic regions were also examined on themethylation level. For
example, researchers have found that the number of short telom-
eres with constant subtelomeric methylation status was smaller
in peripheral leukocytes from Japanese PD patients compared to
the healthy controls (Maeda et al., 2009). Although, based on the
limited number of studies in this field, we cannot come up with
a meaningful conclusion from these findings, but at least there
might be a bold hypothesis that DNAmethylation associates with
PD through a variety of genetic pathways.
ENVIRONMENTAL FACTORS AND DNA METHYLATION IN PD
Environment can significantly affect the risk and progression
of neurodegenerative disorders including PD. Here we synthe-
sized published studies focused on the interaction between DNA
methylation and environmental factors in PD cases.
Elevated plasma homocysteine levels have been documented
in PD individuals (O’Suilleabhain et al., 2004). A further increase
in plasma homocysteine levels of blood cell samples was observed
in individuals with both PD and the MTHFR C677T mutation
(Brattstrom, 2001). PD patients undergoing regular treatment
with L-Dopa had higher plasma homocysteine concentrations
relative to healthy controls, indicating a possible methylated
catabolism of the drug (Blandini et al., 2001). Dietary folate
deficiency and elevated homocysteine levels have been found
to be harmful to dopaminergic neurons in mouse models of
PD (Duan et al., 2002). A recent study found out that hall-
marks of neurodegeneration such as APP and α-synuclein were
related to markers of methylation like SAM and its down-
stream byproduct, S-Adenosyl-L-homocysteine (SAH) in indi-
viduals with PD (Obeid et al., 2009). A higher SAM/SAH ratio,
which indicates a higher methylation potential, was linked to
better cognitive function. Note that the SAM/SAH ratio is a
significant positive predictor of DemTect scores in PD patients
and DemTect is a cognitive screening instrument sensitive to
the early cognitive symptoms of dementia including AD and PD
(Kalbe et al., 2004).
Telomeric dysfunction has been discovered to be associated
with development of age-related pathologies, and similarly to
AD, shortened telomeres were found present in patients with PD
(Guan et al., 2008). Telomere length is epigenetically regulated by
DNA methylation, which in turn could be modulated by folate
status. In human, telomere length has been reported to be associ-
ated with folate status (Paul et al., 2009). Plus, various nutrients
also showed potential to influence regulation of telomere length,
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e.g., folate, via its role in epigenetic status of DNA methylation
and histone modification (Paul, 2011).
Besides, environmental exposure, including paraquat, is
believed to be a risk for PD. Interestingly, a pretreat-
ment of PC12 with 5-aza-2′deoxycytidine, a DNMT inhibitor,
sensitizes cells to paraquat exposition. Similar results were
obtained using dopaminergic cells and treatments of MPP(+),
6-hydroxydopamine and rotenone, (Wang et al., 2013) suggest-
ing that DNA methylation might modulate the effect of these
toxins and might play a role in PD susceptibility (Kong et al.,
2012). These findings underlie a possible mechanism in which
environment influences pathology of PD via DNA methylation
modification. Nevertheless, since data presented so far are too
insufficient to substantiate any hypothesis, further solid findings
are very necessary and helpful to arrive at a reliable conclusion.
DNA METHYLATION AND HUNTINGTON’S DISEASE
INTRODUCTION TO HUNTINGTON’S DISEASE
HD, or Huntington’s chorea, is the most common genetic cause
of chorea in high-income countries, with a prevalence of about
one in 10,000 people. This lethal neurodegenerative disease pri-
marily affects the cerebral cortex and the striatum. Initial physical
symptoms are chorea, rigidity, and dystonia, and become more
apparent as the disorder progresses. Cognitive abilities become
gradually impaired, finally leading to dementia (Babenko et al.,
2012).
HD is caused by the expansion of CAG triplet repeats in the
HTT gene, which encodes an expanded polyglutamine (polyQ)
stretch in the huntingtin (HTT) protein. Normal HTT genes
contain CAG repeats no more than 35, and are not associated
with the disorder. Incomplete penetrance happens with 36–40
repeats. However, when these repeats reach 41 or more, the dis-
ease becomes completely penetrant. The number CAG repeats
accounts for ∼60% of the variation in age of onset, and the rest
can be explained by modifying genes and environment (Walker,
2007).These expanded polyQ sequences in the HTT protein pro-
duce aggregates that form intracellular inclusions, leading to
neural loss, particularly in the caudate nucleus (Rubinsztein and
Carmichael, 2004).
Most studies aimed to find a clear correlation between HD
and DNA methylation focus on two specific subjects: HTT gene
and triplet repeat expansions. In addition to the genetic fac-
tors, environment also plays a vital role in this DNA methylation
-associated mechanism.
GENETIC FACTORS, DNA METHYLATION, AND HD
Researches on DNA methylation in HD began much earlier than
those in PD. In 1988, Wasmuth et al. reported the identification
of a highly polymorphic locus, D4S95, which was demonstrated
to be tightly linked to the HD gene (Wasmuth et al., 1988).
Later, methylation was found at the B5 allele of the D4S95 locus,
which was not inherited in a Mendelian fashion, as its appearance
depended on the methylation status of the human lymphoblas-
toid cells from which DNA samples were obtained (Pritchard
et al., 1989), and such phenomenon disclosed the secret of the
role of DNA methylation in HD. For the first time, Farrer et al.,
in their study of 1764 HD patients explored that DNA methyla-
tion might be involved in a genetic imprinting mechanism, and
thus responsible for the expression of HD (Farrer et al., 1992).
Although a comparison between HD patients and normal con-
trols showed no strong relevance between methylation and onset
age of the disease, a significant association of the patient’s age with
demethylation at D4S95 was found (Reik et al., 1993). A PCR-
amplication of synthetic oligodeoxyribonucleotides revealed that
cytidine methylation could have an impact on the expansion
of triplet repeat sequences (Behnkrappa and Doerfler, 1994).
Another finding that genome-wide demethylation could acceler-
ate instability of CTG/CAG trinucleotide repeats in mammalian
cells, implies that changes in methylation patterns during epi-
genetic reprograming may trigger the intergenerational repeat
expansions, leading to neurological diseases like HD (Gorbunova
et al., 2004).
It has been discovered that there is a region of highly unsta-
ble CAG repeats at the human spinocerebellar ataxia type 7
(SCA7) locus, and this region contains binding sites for CTCF,
a regulatory factor involved in genomic imprinting, chromatin
remodeling, and DNA conformation change (Filippova et al.,
2001). Recently, an investigation in transgenic mice model found
that CpG methylation of CTCF binding sites could further desta-
bilize triplet repeat expansion (Libby et al., 2008), underpinning
the role of DNA methylation in the regulation of neurological
diseases. The HD-associated modification of BDNF gene expres-
sion was found, in the hippocampus of female and male HD
mice independent of methylation increases in the gene sequence,
while there existed a pattern of sex-specific differences in the lev-
els of methylation at individual CpG sites, suggesting that such
differences might explain the differential regulation of BDNF
expression in themale and female brains (Zajac et al., 2010). Since
it has been reported that the loss of BDNF gene transcription is
likely a central factor to the progressive pathology of HD, DNA
methylation might be the explanation of such loss, which, how-
ever, needs further confirmation. Moreover, extensive changes in
DNA methylation were reported to be linked to expression of
mutant huntingtin gene, revealing the potential effects of DNA
methylation alterations on neurogenesis and cognitive decline in
patients with HD (Ng et al., 2013).
Besides, a recent study focused on adenosine A2A receptor
(A2AR), a G-protein-coupled receptor, the expression levels of
which are sharply reduced in HD (Villar-Menendez et al., 2013).
The study found increased 5mC levels and reduced 5hmC levels in
5′UTR region of A2AR gene from HD patients compared to age-
matched controls, suggesting an involvement of an altered methy-
lation pattern of A2AR gene in HD pathology. Moreover, instead
of methylated cytosine, a HPLC-based method also detected lev-
els of 7-methyl guanine in DNA samples both from transgenic
mice and HD patients, revealing aberrant methylation levels in
HD (Thomas et al., 2013), and also widening the range of future
researches on DNA methylation.
DNA METHYLATION AND AMYOTROPHIC LATERAL
SCLEROSIS
INTRODUCTION TO AMYOTROPHIC LATERAL SCLEROSIS
ALS is an idiopathic, fatal neurodegenerative disease of the
humanmotor system. The clinical hallmark of ALS is the presence
of the lower motor neuron signs in brainstem and spinal cord,
and the upper motor neuron signs in the motor cortex. Loss of
Frontiers in Aging Neuroscience www.frontiersin.org December 2013 | Volume 5 | Article 85 | 7
Lu et al. DNA methylation and neurodegenerative diseases
these neurons leads to clinical phenotypes including muscle atro-
phy, weakness, fasciculation, spasticity, and cognitive dysfunction
(Kiernan et al., 2011). Proposed pathogenic mechanisms for ALS
include oxidative stress, glutamate excitotoxicity, impaired axonal
transport, neurotrophic deprivation, neuroinflammation, apop-
tosis, and altered protein turnover, etc. Furthermore, influences
from astrocytes and microglia in the motor neuron microenvi-
ronment contribute to ALS pathogenesis (de Carvalho and Swash,
2011).
ALS is traditionally classified into two categories: familial ALS
(FALS) and sporadic ALS (SALS) (Robberecht and Philips, 2013).
FALS is predominantly hereditary and then almost always auto-
somal dominant, while X-linked or recessive FALS is rare. Several
genes and their mutations have been found to be associated with
ALS. Superoxide dismutase 1 (SOD1) mutations are the cause in
about 20% of FALS. Also, TARDBP, which encodes TAR DNA-
binding protein, and FUS, a RNA- binding protein fused in
sarcoma, also contribute to FALS cases. SALS has been associ-
ated with another gene, ELP3, encoding the catalytic subunit of
the histone acetyltransferase (HAT) complex elongator protein
(Urdinguio et al., 2009). Additionally, ALS2, ATXN2, and some
other genes are also associated with ALS, which we will discuss
below (Ferraiuolo et al., 2011).
Not unlike those neurodegenerative diseases we described
above, there is a potential point that ALS is also connected to DNA
methylation through genetic and environmental factors.
GENETIC FACTORS, DNA METHYLATION, AND ALS
An epigenetic analysis of SOD1 and VEGF (which encodes vas-
cular endothelial growth factor, a signal protein produced by cells
that stimulates vasculogenesis and angiogenesis) in ALS showed
that the promoter regions of these genes were widely unmethy-
lated in ALS patients, suggesting transcriptional silencing via
DNA methylation is not likely a common mechanism in ALS
(Oates and Pamphlett, 2007).
In contrast, methylation of the human glutamate transporter
EAAT2 gene promoter has been reported to be associated with
the silent state of the human EAAT2 gene. Since the dysfunction
of EAAT2 transporter might contribute to the pathogenesis of
ALS (Rothstein et al., 1995), it is meaningful to further test the
regulation of EAAT2 transporter via an epigenetic mechanism
including DNA methylation in ALS models. GLT1 is the analog
to EAAT2 in rodent astroglial cells, however, hypermethylation
on specific CpG islands of GLT1 promoter was discovered to par-
ticipate in repression of GLT1 promoter activation, whereas this
regulation was not involved in astroglial dysfunction of EAAT2 in
ALS patients (Yang et al., 2010). Studies also found that a group
of genes, either unsuspected in SALS or in potential pathways of
cell death, revealed changed methylation status in SALS brains
(Morahan et al., 2009). Because of the controversial findings
above, there are supposed to be more powerful and convincing
evidence collected to clarify the involvement of DNAmethylation
in ALS by regulating the expression of the human EAAT2.
In mouse models, the apoptosis process of motor neurons
showed alterations in DNMT1, DNMT3a, and 5-methylcytosine,
which is similar to those in human ALS, indicating that DNMT
may mediate neuronal cell death through DNA methylation
(Chestnut et al., 2011). In addition, CpG methylation in human
ATXN2 gene promoter is associated with pathogenic CAG expan-
sions in spinocerebellar ataxia type 2 (SCA2) cases (Laffita-Mesa
et al., 2012). Since such aberrant expansions in ATXN2 were
shown to contribute to ALS (Lahut et al., 2012), we can expect
that there might exist a link between ATXN2 promoter methyla-
tion and pathogenesis of ALS.
ENVIRONMENTAL FACTORS AND DNA METHYLATION IN ALS
Environmental exposure to heavy metals has been implicated in
SALS and functionally impaired detoxification of these metals
may cause serious susceptibility to the disease. The metalloth-
ionein (MT) is a family of proteins that are involved in primary
detoxification mechanism for heavy metals. As a matter of fact,
no promoter methylation of human MT genes was evident in any
SALS or control samples, implying the possibility that methy-
lation at these gene promoters may not be a common cause of
SALS (Morahan et al., 2007). However, altered methylation of the
Alsin (ALS2) gene promoter was observed in hippocampal cells of
individuals with a history of being abused in childhood (Labonte
et al., 2012). Interestingly, higher levels of promoter methylation
were correlated with a repression of ALS transcription suggesting
a role of DNA methylation in the regulation of ALS gene.
DISCUSSION
We find three topics worth discussing: (1) causal relationship
between DNA methylation modification and neurodegenerative
diseases, (2) triggers of DNA methylation modification in neu-
rodegenerative diseases, and (3) perspectives.
In the field of neurodegenerative diseases, although experi-
mental evidence revealed correlations between DNA methylation
and these diseases, two major questions remain unclear. The first
question is the causal relationship between DNA methylation
modifications and neurodegenerative diseases. In other words, do
DNA methylation modifications precede the appearance of neu-
rodegenerative symptoms? Is there a proved mechanism demon-
strating that DNA methylation modifications will finally lead to
neurodegenerative diseases? Another question is: if DNA methy-
lation modifications do cause neurodegenerative diseases, what is
the trigger of these methylation modifications in neurodegenera-
tive diseases? This is also a crucial question since it may lead us to
new paths of curing these diseases.
CAUSAL RELATIONSHIP BETWEEN DNA METHYLATION
MODIFICATION AND NEURODEGENERATIVE DISEASES
Alzheimer’s disease
Evidences generally suggested that DNA methylation modifica-
tion is a cause instead of a consequence of AD, for several events
related to DNA methylation occur earlier than AD symptoms.
One clue is that the upregulation of plasma homocysteine
(HCY), an independent AD risk factor, occurs prior to the
pathogenesis of AD (Clarke et al., 1998; Seshadri et al., 2002).
As we know, DNA methylation is accomplished by transfer-
ring a methyl group from SAM to the 5-position of cytosine.
This metabolic pathway belongs to HCY metabolism (one-
carbon metabolism). HCY accumulation leads to upregulation
of S-adenosylhomocysteine (SAH) levels due to the reversibility
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of the reaction. To make the reaction proceed in the hydrolytic
direction, HCY and Ado have to be efficiently removed (Fuso
et al., 2005) (Figure 1). SAH, a strong DNA methyltransferase
inhibitor, strengthens DNA hypomethylation. Thus, a regula-
tion of metabolism through either remethylation or transsulfu-
ration pathways may result in hyperhomocysteinemia, decrease
of SAM/SAH ratio (also called methylation potential, MP), and
change of GSH levels, suggesting that hypomethylation is a mech-
anism through which HCY is related to vascular disease and
AD. Additionally, oxidative stress was shown to promote the
production of HCY’s oxidized derivatives, such as homocysteic
acid and homocysteine sulfinic acid. These compounds inter-
act with glutamate receptors thus increasing intracellular free
radicals (Fuso and Scarpa, 2011). Following this trail, a series
of studies demonstrated PS1 gene promoter hypomethylation
in cell and mouse models under alterative HCY case (Scarpa
et al., 2003; Fuso et al., 2005, 2007, 2008). These cases are often
accomplished by deficiency of vitamin B6, vitamin B12 and
folate during cell culture and mouse feeding. Moreover, in SK-
N-BE neuroblastoma cells and TgCRND8 mice, such a trend
is found to be reverted when SAM was intentionally added to
the culture or diet (Fuso et al., 2011b). Cognitive experiments
in mice and detection of Aβ formation confirmed these results
(Fuso et al., 2012b). It has also been shown that the activi-
ties of DNA methyltransferases (DNMT1, DNMT3A, DNMT3B)
and demethylase (MBD2) are modulated by HCY metabolism in
AD cells and mouse models. Elevated HCY levels decreased the
activity of DNA methylase and the activity of DNA demethy-
lase was increased (Fuso et al., 2011a). Since the elevation in
the homocysteine level preceded the onset of dementia, stud-
ies from this area implies that global DNA hypomethylation is a
cause of AD.
DNAmethylation regulation in aging offers another clue to the
causal relationship. Aging is generally considered to be one of the
most salient risk factors for AD, and a strong correlation between
DNA methylation regulation and aging was demonstrated in
brain and blood samples (Horvath et al., 2012). Decrement
of S100A2 and increment in SORBS3 CpG methylation in the
human cerebral cortex during aging was reported, and an accel-
eration of this trend was shown in AD patients (Siegmund et al.,
2007). Another study including 24 LOAD brains and 10 matched
controls revealed epigenetic variability of genes related to AD
among all individuals, and AD patients’ epigenetic distance from
the norm was observed to increase progressively with age. It was
suggested that epigenetic modifications may merely result in a
range of interindividual variance until a threshold of epigenetic
deregulation is reached. After this point, the brain starts to mal-
function and AD symptoms occur. Based on this view, LOADmay
represent an extreme form of normal aging (Wang et al., 2008). To
sum up, these studies indicated that methylation changes are parts
of aging, and some of them may result in AD.
It is noteworthy that there are results from another side. In
a murine cerebral endothelial cells model, it was shown that
Aβ reduces global DNA methylation whilst increasing NEP’s
DNA methylation level and further suppressing NEP’s expres-
sion in mRNA and protein levels (Chen et al., 2009). This finding
suggested a vicious cycle formed by DNA methylation alteration
and Aβ production, in which these two phenomena reinforce each
other and cause AD eventually. This point is interesting, however,
most other studies of this kind showed the opposite result. For
instance, a recent study showed that amyloid production was not
responsible for PS1 demethylation in the brain of TgCRND8mice
(carrying a double-mutated human APP transgene) (Fuso et al.,
2012a). Therefore, such results need to be further analyzed.
Parkinson’s disease, Huntington’s disease, and amyotrophic lateral
sclerosis
Similar to AD, the other three major neurodegenerative diseases,
i.e., PD, HD, and ALS, are also closely related to DNAmethylation
of several critical genetic loci. While these loci have been exten-
sively studied, some findings seem to disagree with others. In the
case of PD, α-synuclein gene is the research spot of interest. There
have been a series of studies of human PD brain cell samples that
tested the DNA methylation level of the promoter and intron 1
of α-synuclein gene and found a different methylation level com-
pared to normal controls (Jowaed et al., 2010; Matsumoto et al.,
2010; de Boni et al., 2011). These findings all support the idea
that DNA methylation is involved in PD. However, some other
results are not so positive as they found, while examining blood
cell samples of PD patients, that α-synuclein expression was not
changed (Richter et al., 2012), or its expression changed indepen-
dent of DNA methylation modification (Voutsinas et al., 2010).
This seems a little controversial, but if we take a closer look at
these results against the involvement of DNA methylation in PD,
we can find that these examinations taken with blood cell samples
are much less convincing than those taken with brain cell samples
in that α-synuclein is widely believed to mainly be localized and
functional in mammalian brain neurons (Mclean et al., 2000; Yu
et al., 2007). Other genetic loci with issues are parkin and UCHL1
genes, which also play important roles in PD pathology, however,
due to lack of enough evidence so far, we still cannot determine
whether these loci are affected by DNA methylation or not.
In the case of HD and ALS, the studies were merely focused on
the rough relationship between these diseases and DNA methy-
lation. Although, of course, there are some genetic loci that also
have been examined in those researches such as CTCF, BDNF, and
ATXN, we can barely come to any specific conclusion because of
the poor quantity of scientific evidence.
TRIGGERS OF DNA METHYLATION MODIFICATIONS IN
NEURODEGENERATIVE DISEASES
Alzheimer’s disease
Knowing that DNAmethylation changes do interact with AD and
usually serve as causes, one may seek the origin of these changes
in DNA methylation patterns. Such pursuit is worthwhile since
it may finally guide us to a new path for treating AD. We divide
possible causes of DNA methylation regulation in AD into four
aspects: aging, B vitamin deficiency, oxidative stress, and heavy
metal exposure.
Aging factors. As we mentioned above, aging is a widely-accepted
risk factor of AD, and some reports regarded methylation change
related to AD as an acceleration of aging (Siegmund et al., 2007)
or a specialized case of aging (Wang et al., 2008). These studies
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provide a chain of causation from aging to DNA methylation
deregulation and then to AD.
B vitamin deficiency. As we know, DNA methylation is accom-
plished by transferring a methyl group from SAM to the
5-position of cytosine and this metabolic pathway belongs to
HCY metabolism (one-carbon metabolism). Folate, vitamin B6
and vitamin B12 are crucial for this metabolic cycle since N5-
methyl-tetrahydrofolate (N5-methyl-THF, a folate derivative)
donates a methyl group to HCY that then transforms to methion-
ine while vitamin B6 and vitamin B12 are involved in methylation
catalysis. Therefore, the deficiency of vitamin B may block the
regular DNA methylation metabolic cycle. This indication is sup-
ported by experimental evidence in rats (Miller et al., 1994), and B
vitamin deficiency is commonly used as a method to create DNA
methylation metabolism disorder in current studies (Fuso et al.,
2005, 2011b; Chen et al., 2009). In addition to those hypermethy-
lation and hypomethylation patterns we mentioned above, it was
demonstrated that SAH increased DNA damage in BV-2 cells pos-
sibly by increasing Aβ formation that led to increased formation
of ROS. Furthermore, the DNA damage was reinforced by SAH
through inhibition of DNMT1 activity and hypomethylation of
OGG1 gene promoter in microglial BV-2 cells (Lin et al., 2011).
Moreover, HCY inhibits the dimerization of ApoE3 and
reduces ApoE3-mediated high-density lipoprotein (HDL) gener-
ation (Minagawa et al., 2010). It was shown that HDL apolipopro-
teins can significantly enhance the degradation of soluble Aβ
within microglia, and such degradation was facilitated by the lip-
idation of ApoE (Jiang et al., 2008). HCY was reported to impair
ApoE3 dimerization and ApoE3’s ability of generating HDL by
binding to cysteine residues of ApoE3. Therefore, hyperhomocys-
teinemia may promote the pathogenesis of AD (Minagawa et al.,
2010).
Oxidative stress. Causing the imbalance between DNA methy-
lation and demethylation, oxidative stress is also known as an
environmental factor interacting with DNA methylation and AD.
Study in SH-SY5Y cells revealed that treatment with H2O2 may
activate a DNMT inhibitor and result in the upregulation of APP
and BACE1 through transcription activator-vB, leading to the
upregulation of Aβ production (Gu et al., 2013).
Heavy metal exposure. Infant exposure to lead (Pb) was reported
as another environmental factor contributing to AD through
DNAmethylation regulation. Developmental exposure of rodents
to the heavy metal lead has been shown to increase APP and
Aβ in aging brain (Basha et al., 2005). Study in aged monkeys
showed that the group that was fed with Pb in their early life has
a lower DNMT activity. The downregulation of DNMT activity
thus results in the hypomethylation of several genes involved in
Aβ formation such as APP and BACE, and causes the upregu-
lation of APP, BACE, and Sp1 in turn, which finally results in
Aβ formation and AD (Wu et al., 2008). These finding are con-
firmed by a genome-wide study on mice (Bihaqi et al., 2011) and
an in vitro study (Bihaqi and Zawia, 2012). A latent early-life
associated regulation (LEARn) model, which claims that envi-
ronmental agents perturb gene regulation at early stage but do
not have pathological results until later in life, was proposed to
explain these phenomena (Lahiri et al., 2008; Lahiri andMaloney,
2012).
Parkinson’s disease, Huntington’s disease, and amyotrophic lateral
sclerosis
Compared to AD, the studies are relatively insufficient about the
causal relationship between DNA methylation and other three
neurodegenerative diseases as well as the causes of DNA methyla-
tion in these diseases. Despite paucity of evidences, a few studies
showed that environmental factors such as exposure to toxicity
like paraquat and previous physical and mental experiences like a
history of being abused in childhood, are related to DNA methy-
lation in these diseases. However, data we can search so far are so
rough and random findings that no reliable conclusion but sim-
ply assumptions can be made from them. Therefore, we can see a
promising field of interest waiting for further solid research find-
ings to confirm the hypothesis that similar to AD, there is also a
causal relationship between DNAmethylation and the other three
neurodegenerative diseases (PD, HD, and ALS).
PERSPECTIVES
Expanding rapidly as it is, the field of DNA methylation and neu-
rodegenerative diseases is facing three main challenges for further
progress.
First of all, DNA methylation is an emerging field with many
unclear issues. For instance, one may expect that the hyperme-
thylation will result in the repression of a gene, however, some
opposite findings have been reported, such as the coexistence of
overexpression and DNAmethylation of the p16INK4a gene (Kim
and Sharpless, 2006). Without an accurate comprehension of the
relationship betweenDNAmethylation and the regulation of gene
expression, much experimental evidence linking DNA methy-
lation and neurodegenerative diseases may have been misinter-
preted ormissed. In addition, 5hmC, which used to be regarded as
only an intermediate in DNA demethylation, was recently found
to increase with age in the absence of 5mC changes and thus may
serve as an epigenetic factor of AD (Chen et al., 2012). With the
majority of current studies concentrated on normal CpG methy-
lation, we cannot ignore that non-CpG methylation and 5hmC
also play an important role in DNAmethylation. Since it has been
suggested that non-CpG methylation and 5hmC are dominant
in mammalian brain development (Lister et al., 2013), and since
5hmC is implicated in aging and AD (van den Hove et al., 2012),
further studies should include these specific cases in order to give
us a better understanding of how the DNA methylation is exactly
related to the pathologies of neurodegenerative diseases.
Another challenge is that DNA methylation patterns vary
in different cells as well as different brain regions. Study in
human frontal cortex showed that neurons and glial cells do not
share a same DNA methylation profile, nor do different neurons
(Iwamoto et al., 2011). Since each type of cells in nervous system
plays a distinct role, research ignoring variation among cells may
not be able to provide sufficient evidence for this topic. Moreover,
different regions of the brain, which have various importance
in neurodegenerative diseases, were shown to express genes dif-
ferently (Twine et al., 2011). Therefore, conclusions cannot be
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Table 1 | Altered DNA methylation profiles observed in neurodegenerative diseases.
Disease Category of genes Specific genetic loci DNA methylation regulation Possible effect
AD Aβ-related genes APP Hypomethylation or none Over expression of Aβ
PSEN1 Hypomethylation
BACE1 Hypomethylation
APBA2 Hypermethylation
Aβ-degradation-related genes NEP Hypermethylation Aβ accumulation
SORL1 Hypermethylation
Tau-related genes GSK3β Hypomethylation Disorder of tau
Genes involved in metabolic
pathways
OTC Hypomethylation Metabolic dysfunction
rDNA rDNA Hypermethylation Ribosomal deficits
Others Circadian gene (PER1
and CRY1)
Hypermethylation Behavioral and psychological symptoms
LINE-1 Hypermethylation Unknown
NGB Unknown AD severity regulation
Telomere Hypomethylation Cell entering into a senescent state
COX-2 Hypomethylation Brain AA cascade enzymes upregulation
BDNF Hypermethylation Loss of neurotrophic factors
CREB Hypermethylation Exacerbation of BDNF reduction
SYP Hypermethylation Loss of synaptic proteins
NF-kB Hypomethylation Neuroinflammation
S100A2 Hypomethylation Protein accumulation
SORBS3 Hypermethylation Cell adhesion dysfunction
PD SNCA SNCA (intron1 and
promoter)
Hypermethylation Decreased expression of SNCA
Hypomethylation Overexpression of SNCA
Inflammatory cytokines TNF-α Hypomethylation Increased risk of apoptosis in
dopaminergic neurons
Clock genes CRY1
NPAS2
Devoid of methylation Disorder of circadian rhythms
Telomere Subtelomeric region Constant methylation Telomere shortening
Other genes PARK16/1q32
GPNMB
STX1B
Methylation alteration PD risk
Cytochrome P45 2E1 Hypomethylation Increased PD susceptibility
HD HTT gene Promoter region of HTT
gene
Extensive methylation alteration Neurogenesis and cognition
Oligodeoxyribonucleotides Cytidine Hypermethylation Expansion of triplet repeat sequences
Genome Genome-wide Hypomethylation Instability of CTG/CAG trinucleotide
repeats
CTCF CTCF binding sites CpG methylation
BDNF Promoter region of
BDNF
Gender-specific methylation Differential regulation of BDNF gene
expression
ALS SOD1
VEGF
Promoter regions of
SOD1 and VEGF
Hypomethylation No transcriptional silencing
EAAT2 Promoter regions of
EAAT2
Hypermethylation Functional loss of EAAT2 transporters
GLT1 Promoter region of
GLT1
Hypermethylation
ATXN2 Promoter region of
ATXN2
Hypermethylation Pathogenic CAG expansions
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reached from studies merely focusing on one particular region of
the brain.
The third challenge is the limitation in researchmethods. Most
evidence of DNA methylation modification in neurodegenera-
tive diseases was obtained from postmortem studies. Although
this method was shown to preserve DNA methylation patterns
successfully (Barrachina and Ferrer, 2009), it can only demon-
strate the circumstance of one particular moment. Accordingly,
the correlation between DNA methylation and neurodegenera-
tive diseases can be revealed, but the time sequence of them is
unable to be tracked. Such a limitation leads to the difficulty in
determining the causal relationship of these events.
Hence, in the future, integrated and dynamic studies may
significantly facilitate the development of this promising field.
Comprehensive studies considering the difference among cell
types and brain regions will certainly improve our understand-
ing of this field. Furthermore, since DNA methylation is not an
isolated process, studies must also consider interactions between
DNAmethylation and other epigenetic modifications such as his-
tone acetylation. Although tracking the methylation status in a
living animal cannot be achieved so far, it is possible to reach
a dynamic perception via comparing postmortem results from
samples with different ages, and such a strategy was used in some
remarkable researches recently (Hon et al., 2013; Lister et al.,
2013). Combined with the age-specific detection of neurodegen-
erative diseases, this type of studies will have great significance
in uncovering the pathogenesis of neurodegenerative diseases,
especially in the analysis of causal relationship between DNA
methylation and such diseases.
CONCLUSION
In sum, the correlation between DNA methylation and neurode-
generative diseases has been pointed by numerous studies. These
findings further indicated that DNAmethylation alteration is one
of the causes for neurodegenerative diseases (Table 1). As we dis-
cussed, environmental factors, as well as other possible factors
like aging, are responsible for these alterations and may guide us
to a new path of treating neurodegenerative diseases. Finally, this
area is still filled with unsolved problems and waiting for further
investigations to reveal these secrets, in order to give us a more
comprehensive knowledge of how DNA methylation is involved
in neurodegenerative diseases.
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